Pharsight

Drugs that contain Bivalirudin

1. Angiomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5196404 SANDOZ Inhibitors of thrombin
Dec, 2014

(9 years ago)

US5196404

(Pediatric)

SANDOZ Inhibitors of thrombin
Jun, 2015

(8 years ago)

US7582727 SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

US7598343 SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

US7598343

(Pediatric)

SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(4 years from now)

US7582727

(Pediatric)

SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jan, 2029

(4 years from now)

Market Authorisation Date: 15 December, 2000

Treatment: Inhibition of thrombin in a patient

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage

ANGIOMAX family patents

Family Patents

2. Angiomax Rtu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11903993 MAIA PHARMS INC Ready-to-use bivalirudin compositions
May, 2039

(14 years from now)

US11918622 MAIA PHARMS INC Ready-to-use bivalirudin compositions
May, 2039

(14 years from now)

Market Authorisation Date: 25 July, 2019

Treatment: Use as an anticoagulant in patients undergoing percutaneous coronary intervention (pci)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ANGIOMAX RTU family patents

Family Patents